Somatostatin imaging of neuroendocrine-differentiated prostate cancer - Abstract

After prolonged androgen deprivation therapy, a subset of castrate-resistant prostate cancer patients will develop neuroendocrine prostate cancer (NEPC) associated with resistance to further hormonal therapy and frequent visceral metastases.

Imaging the presence of somatostatin receptors on the cancer cell surface may provide a readily available, noninvasive means to distinguish adenocarcinoma from NEPC. This distinction is important for therapeutic decision making and may open the door for developing novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer. We describe a case of NEPC successfully imaged using In-labeled octreotide.

Written by:
Hope TA, Aggarwal R, Simko JP, VanBrocklin HF, Ryan CJ.   Are you the author?
Department of Radiology and Biomedical Imaging; Division of Hematology/Oncology, Department of Medicine, Departments of Pathology, Urology, and Radiation Oncology, University of California San Francisco, San Francisco, CA.

Reference: Clin Nucl Med. 2015 Mar 17. Epub ahead of print.

PubMed Abstract
PMID: 25783510 Prostate Cancer Section